[go: up one dir, main page]

WO2022118270A1 - Oligosaccharides de lait humain destinés à être utilisés pour favoriser la durée du sommeil nocturne - Google Patents

Oligosaccharides de lait humain destinés à être utilisés pour favoriser la durée du sommeil nocturne Download PDF

Info

Publication number
WO2022118270A1
WO2022118270A1 PCT/IB2021/061288 IB2021061288W WO2022118270A1 WO 2022118270 A1 WO2022118270 A1 WO 2022118270A1 IB 2021061288 W IB2021061288 W IB 2021061288W WO 2022118270 A1 WO2022118270 A1 WO 2022118270A1
Authority
WO
WIPO (PCT)
Prior art keywords
hmo
lacto
lnt
use according
infant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2021/061288
Other languages
English (en)
Inventor
Jonas HAUSER
Clara Lucia Garcia-Rodenas
Weili Lin
Seoyoon CHO
Ziliang ZHU
Tengfei Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycom AS
Original Assignee
Glycom AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycom AS filed Critical Glycom AS
Publication of WO2022118270A1 publication Critical patent/WO2022118270A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • This invention relates to human milk oligosaccharides (HMOs) for use in a non-infants to support better sleep quality and improve night sleep duration.
  • HMOs human milk oligosaccharides
  • HMOs human milk oligosaccharides
  • Reduced sleep has been associated with multiple negative effects, such as decreased cognitive development, mood regulation, and overall health (L.J. Meltzer, J. A. Mindell Psychiatr. Clin. North Am. 29, 1059 (2006)). Specifically, short sleep duration and poor sleep quality has been associated with obesity (E.M. Taveras et al. Arch. Pediatr. Adolesc. Med. 162, 305 (2008)) and behavioural problems (B. Zuckerman et al. Pediatrics 80, 664 (1987)). The most common sleep disturbances in infants and children are those related to wakefulness (i.e. either difficulties in settling at bedtime or failure to sleep through the night without interruptions). It has been estimated that these disturbances affect 15 to 35 % of infants aged less than 24 months (France et al. Sleep Medicine Reviews 3, 265 (1999)).
  • HMOs have been implicated since HMOs are largely metabolized in the intestinal tracts.
  • the potential effects of HMOs on brain functional development are less studied, and most studies in this field focused on learning and memory.
  • Vazquez et al. J. Nutr. Biochem. 26, 455 (2015) demonstrated that the treated animals exhibit significantly better learning and working memory functions.
  • the present study is the first study reporting human results and investigating impact of HMO on sleep duration.
  • this invention provides one or more human milk oligosaccharides (HMOs) for use in improving the total night sleep duration or sleep quality in a non-infant.
  • HMOs human milk oligosaccharides
  • this invention provides a synthetic composition comprising, consisting of or consisting essentially of an effective amount one or more human milk oligosaccharides (HMOs) for use in improving the total night sleep duration or sleep quality in a non-infant.
  • HMOs human milk oligosaccharides
  • the nutritional composition comprises a total amount of the one or more HMOs from 50 mg to 5000 mg/l, for example from 50 mg to 2500 mg/l, or 60 mg to 2000 mg/l, or from 80 mg to 1000 mg/l.
  • this invention provides a pack for use in improving the total night sleep duration or sleep quality in a non-infant, the pack comprising at least 14 individual daily doses of an effective amount of one or more human milk oligosaccharides (HMOs).
  • HMOs human milk oligosaccharides
  • the pack preferably comprises at least about 21 individual daily doses, for example about 28 daily doses.
  • a fourth aspect of the invention is a use of one or more human milk oligosaccharides (HMOs), a synthetic composition comprising, consisting of or consisting essentially of one or more human milk oligosaccharides (HMOs), or a pack comprising at least 14 individual daily doses of an effective amount of one or more human milk oligosaccharides (HMOs) in the dietary management of a non-infant human suffering from sleeping problems associated to the total night sleep duration or sleep quality.
  • HMOs human milk oligosaccharides
  • a synthetic composition comprising, consisting of or consisting essentially of one or more human milk oligosaccharides (HMOs), or a pack comprising at least 14 individual daily doses of an effective amount of one or more human milk oligosaccharides (HMOs) in the dietary management of a non-infant human suffering from sleeping problems associated to the total night sleep duration or sleep quality.
  • this invention provides a method for improving the total night sleep duration or sleep quality in a non-infant, the method comprising administering to the non-infant human an effective amount of one or more human milk oligosaccharides (HMOs).
  • HMOs human milk oligosaccharides
  • the total night sleep duration is increased by at least 30 minutes or more. In one embodiment of any of the aspects above, the improvement of the sleep quality is characterized by longer nights without being unwillingly awake and by a more peaceful sleep.
  • the one or more HMOs are selected from the group consisting of a sialylated HMO, a non-fucosylated neutral HMO and a combination thereof. More preferably, the sialylated HMO is a sialyllactose, particularly 3'-SL; and/or the non-fucosylated neutral HMO is selected from the group consisting of LNT, LNnT, LNH, LNnH, pLNH and pLNnH, particularly LNT and LNnT.
  • the non-infant human is administered the one or more HMOs for a period of at least 1 week, more preferably for at least 2 weeks.
  • the human can be administered the one or more HMOs for a period of at least 4 weeks or even more.
  • the non-infant human may be administered a dose of one or more HMOs of about 0.2 to 10 g per day.
  • the non-infant human may be administered a higher dose initially followed by a lower dose of one or more HMOs.
  • the higher dose is preferably about 0.5 g to about 10 g per day (for example about 1 g to about 7.5 g per day) and the lower dose is preferably about 0.1 g to about 5 g per day (for example about 0.2 g to about 3 g per day).
  • Dietary management means exclusive or partial feeding of patients who, because of a disease, disorder or medical condition are suffering from: either have a limited, impaired or disturbed capacity to take, digest, absorb, metabolise or excrete ordinary food or certain nutrients contained therein, or metabolites, or have other medically-determined nutrient requirements
  • Enteral administration means any conventional form for delivery of a composition to a human that causes the deposition of the composition in the gastrointestinal tract (including the stomach). Methods of enteral administration include feeding through a naso-gastric tube or jejunum tube, oral, sublingual and rectal. "Effective amount” means an amount of a composition that provides a HMO in a sufficient amount to render a desired treatment outcome in a human. An effective amount can be administered in one or more doses to achieve the desired treatment outcome.
  • FODMAP means fermentable oligosaccharides, disaccharides, monosaccharides and polyols.
  • Human milk oligosaccharide or "HMO” means a complex carbohydrate found in human breast milk (Urashima et al.: Milk Oligosaccharides. Nova Science Publisher (2011); Chen Adv. Carbohydr. Chem. Biochem. 72, 113 (2015)).
  • the HMOs have a core structure comprising a lactose unit at the reducing end that can be elongated by one or more p-N-acetyl-lactosaminyl and/or one or p-more lacto-N-biosyl units, and which core structure can be substituted by an a L-fucopyranosyl and/or an a-N-acetyl-neuraminyl (sialyl) moiety.
  • the non-acidic (or neutral) HMOs are devoid of a sialyl residue, and the acidic HMOs have at least one sialyl residue in their structure.
  • the non-acidic (or neutral) HMOs can be fucosylated or non- fucosylated.
  • neutral non-fucosylated HMOs include lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-neohexaose (LNnH), para-lacto-N-neohexaose (pLNnH), para-lacto-N-hexaose (pLNH) and lacto-N-hexaose (LNH).
  • neutral fucosylated HMOs examples include 2'-fucosyl lactose (2'-FL), lacto-N-fucopentaose I (LNFP-I), lacto-N-difucohexaose I (LNDFH-I), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose II (LNFP-I I), lacto-N-fucopentaose III (LNFP-III), lacto-N-difucohexaose III (LNDFH-III), fucosyl-lacto-N- hexaose II (FLNH-II), lacto-N-fucopentaose V (LNFP-V), lacto-N-fucopentaose VI (LNFP-VI), lacto- N-difucohexaose II (LNDFH-I
  • acidic HMOs examples include 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), 3- fucosyl-3’-sialyllactose (FSL), LST a, fucosyl-LST a (FLST a), LST b, fucosyl-LST b (FLST b), LST c, fucosyl-LST c (FLST c), sialyl-LN H (SLNH), sialyl-lacto-N-hexaose (SLNH), sia lyl-lacto-N- neohexaose I (SLNH-I), sialyl-lacto-N-neohexaose II (SLNH-II) and disialyl-lacto-N-tetraose (DSLNT).
  • 3'-SL 3'-sialyllactose
  • 6'-SL 6-s
  • “Improvement of sleep quality” is characterized, comprised or is limited to the reduction of the number of episodes of wake states. The improvement of sleep quality is characterized by longer nights without being unwillingly awake and by a more peaceful sleep.
  • "Microbiota”, “microflora” and “microbiome” mean a community of living microorganisms that typically inhabits a bodily organ or part, particularly the gastro-intestinal organs of humans.
  • the most dominant members of the gastrointestinal microbiota include microorganisms of the phyla of Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, Synergistetes, Verrucomicrobia, Fusobacteria, and Euryarchaeota, at genus level Bacteroides, Faecalibacterium, Bifidobacterium, Roseburia, Alistipes, Colli nsella, Blautia, Coprococcus, Ruminococcus, Eubacterium and Dorea, at species level Bacteroides uniformis, Alistipes putredinis, Parabacteroides merdae, Ruminococcus bromii, Dorea longicatena, Bacteroides caccae, Bacteroides thetaiotaomicron, Eubacterium hallii, Ruminococcus torques, Faecalibacterium prausnitzii, Ruminococcus lactaris, Collinsella aerofaci
  • the gastrointestinal microbiota includes the mucosa-associated microbiota, which is located in or attached to the mucous layer covering the epithelium of the gastrointestinal tract, and luminal-associated microbiota, which is found in the lumen of the gastrointestinal tract.
  • Modulating of microbiota means exerting a modifying or controlling influence on microbiota, for example an influence leading to an increase in the indigenous intestinal abundance of Bifidobacterium, Barnesiella, Faecalibacterium and/or butyrate producing bacteria. In another example, the influence may lead to a reduction of the intestinal abundance of Ruminococcus gnavus and/or Proteobacteria.
  • Proteobacteria are a phylum of Gram-negative bacteria and include a wide variety of pathogenic bacteria, such as Escherichia, Salmonella, Vibrio, Helicobacter, Yersinia and many other notable genera.
  • Non-infant human or “non-infant” means a human of 3 years of age and older.
  • a non-infant human can be a child, a teenager, an adult or an elderly person, preferably a teenager, an adult or an elderly person, more preferably an adult or an elderly person.
  • Oral administration means any conventional form for the delivery of a composition to a human through the mouth. Accordingly, oral administration is a form of enteral administration.
  • Synthetic composition means a composition which is artificially prepared and preferably means a composition containing at least one compound that is produced ex vivo chemically and/or biologically, e.g. by means of chemical reaction, enzymatic reaction or recombinantly
  • the synthetic composition typically comprises one or more HMOs.
  • the synthetic compositions may comprise one or more nutritionally or pharmaceutically active components which do not affect adversely the efficacy of the HMOs.
  • Total night sleep duration means a total time spent sleeping during night by the subject. The term encompasses a better sleep and/or limited nocturnal awaking by the subject. The term “improving total night sleep duration” would be an increase in sleep time by over at least 30 minutes or approximately one hour or more.
  • the sialylated HMOs and non-fucosylated neutral HMOs can be isolated or enriched by well- known processes from milk(s) secreted by mammals including, but not limited to human, bovine, ovine, porcine, or caprine species. They can also be produced by well-known processes using microbial fermentation, enzymatic processes, chemical synthesis, or combinations of these technologies.
  • LNT can be synthesized as described in WO 2012/155916 and WO 2013/044928
  • a mixture of LNT and LNnT can be made as described in WO 2013/091660
  • sialylated oligosaccharides can be made as described in WO 2012/113404.
  • sialylated oligosaccharides can be made as described in WO 2012/007588.
  • Biotechnological methods which describe how to make core (non-fucosylated neutral) human milk oligosaccharides optionally substituted by fucose or sialic acid using genetically modified E. coli con be found in WO 01/04341 and WO 2007/101862.
  • the present invention relates to a sialylated HMO, preferably a sialyllactose, more preferably 3'-sia lyllactose (3'-SL) for use in improving total night sleep duration or sleep quality in a non-infant.
  • a sialylated HMO preferably a sialyllactose, more preferably 3'-sia lyllactose (3'-SL) for use in improving total night sleep duration or sleep quality in a non-infant.
  • the present invention relates to non-fucosylated neutral HMO for use in improving total night sleep duration or sleep quality in a non-infant.
  • the non- fucosylated HMO is selected from lacto-N-tetraose (LNT), lacto-N-neotetraose, p-lacto-N- hexaose (pLNH), p-lacto-N-neohexaose (pLNnH), lacto-N-hexaose (LNH) or lacto-N-neohexaose (LNnH), more preferably LNT.
  • the present invention relates to a combination of a sialylated HMO and a non-fucosylated neutral HMO for use in improving total night sleep duration or sleep quality in a non-infant.
  • the sialylated HMO is a sialyllactose, more preferably 3'-sialyl lactose (3'-SL)
  • the non-fucosylated HMO is selected from lacto-N-tetraose (LNT), lacto-N-neotetraose, p-lacto-N-hexaose (pLNH), p-lacto-N-neohexaose (pLNnH), lacto-N-hexaose (LNH) and lacto-N- neohexaose (LNnH), more preferably LNT.
  • LNT lacto-N-tetraose
  • pLNH lacto-N-neo
  • the sialy lated HMO and/or the non-fucosylated neutral HMO may be complemented with other human milk oligosaccharides.
  • the sialylated a nd/or non-fucosylated neutral HMO may be complemented with a fucosylated HMO selected from 2'-FL, 3-FL and DFL.
  • sialylated and/or non-fucosylated neutral HMO can be used as it is or they are (neat), without any carrier and/or diluent.
  • sialylated and/or non-fucosylated neutral HMO is/are used in a synthetic composition with one or more inert carriers/diluents that are acceptable in nutritional or pharmaceutical compositions, for example solvents (e.g. water, water/ethanol, oil, water/oil), dispersants, coatings, absorption promoting agents, controlled release agents, inert excipients (e.g. starches, polyols, granulating agents, microcrystalline cellulose, diluents, lubricants, binders, disintegrating agents).
  • solvents e.g. water, water/ethanol, oil, water/oil
  • dispersants e.g. water, water/ethanol, oil, water/oil
  • coatings e.g. water, water/ethanol, oil, water/oil
  • compositions do not contain prebiotic and/or probiotic [that is: a synthetic composition consisting of a) sialylated and/or non-fucosylated neutral HMO, b) one or more inert carriers/diluents that are acceptable in nutritional or pharmaceutical compositions].
  • the sialylated and/or non-fucosylated neutral HMO is/are used in a synthetic pharmaceutical or nutritional composition that may contain a prebiotic and/or probiotic.
  • the following embodiments for use in improving the total night sleep duration or sleep quality in a non-infant are especially comprised: a single HMO which is 3'-SL, a single HMO which is LNT, exactly two HMOs which are 3'-SL and LNT (a mixture of HMOs consisting of or consisting essentially of 3'-SL and LNT),
  • LNT a synthetic composition comprising, consisting of or consisting essentially of 3'-SL and at least a further non-fucosylated neutral HMO different than LNT
  • a synthetic composition comprising, consisting of or consisting essentially of LNT and at least a further sia lylated HMO different than 3'-SL
  • a synthetic composition comprising, consisting of or consisting essentially of 3'-SL and at least a further non-fucosylated neutral HMO different than LNT.
  • the present invention relates to a nutritional composition
  • a nutritional composition comprising 3'- sialyllactose (3'-SL) and lacto-N-tetraose (LNT) for use in improving total night sleep duration or sleep quality in a subject.
  • 3'-SL 3'- sialyllactose
  • LNT lacto-N-tetraose
  • the preferred non-infant humans are selected from the group consisting of a child, a teenager, an adult and an elderly person, more preferably selected from the group consisting of a teenager, an adult and an elderly person, even more preferably selected from the group consisting of an adult and an elderly person.
  • the preferred embodiments of the daily doses comprised in the pack according to the third aspect are those disclosed above.
  • the synthetic composition can be in the form of a nutritional composition.
  • the nutritional composition can be a food composition, a rehydration solution, a medical food or food for special medical purposes, a nutritional supplement and the like.
  • the nutritional composition can contain sources of protein, lipids and/or digestible carbohydrates and can be in powdered or liquid forms.
  • the composition can be designed to be the sole source of nutrition or as a nutritional supplement.
  • Suitable protein sources include milk proteins, soy protein, rice protein, pea protein and oat protein, or mixtures thereof.
  • Milk proteins can be in the form of milk protein concentrates, milk protein isolates, whey protein or casein, or mixtures of both.
  • the protein can be whole protein or hydrolysed protein, either partially hydrolysed or extensively hydrolysed. Hydrolysed protein offers the advantage of easier digestion which can be important for humans with inflamed or compromised Gl tracts.
  • the protein can also be provided in the form of free amino acids.
  • the protein can comprise about 5 % to about 30 % of the energy of the nutritional composition, normally about 10 % to 20 %.
  • the protein source can be a source of glutamine, threonine, cysteine, serine, proline, or a combination of these amino acids.
  • the glutamine source can be a glutamine dipeptide and/or a glutamine enriched protein.
  • Glutamine can be included due to the use of glutamine by enterocytes as an energy source.
  • Threonine, serine and proline are important amino acids for the production of mucin. Mucin coats the gastrointestinal tract and can improve intestinal barrier function and mucosal healing.
  • Cysteine is a major precursor of glutathione, which is key for the antioxidant defences of the body.
  • Suitable digestible carbohydrates include maltodextrin, hydrolysed or modified starch or corn starch, glucose polymers, corn syrup, corn syrup solids, high fructose corn syrup, rice-derived carbohydrates, pea-derived carbohydrates, potato-derived carbohydrates, tapioca, sucrose, glucose, fructose, sucrose, lactose, honey, sugar alcohols (e.g. maltitol, erythritol, sorbitol), or mixtures thereof.
  • the composition is reduced in or free from added lactose or other FODMAP carbohydrates.
  • Generally digestible carbohydrates provide about 35 % to about 55 % of the energy of the nutritional composition.
  • a particularly suitable digestible carbohydrate is a low dextrose equivalent (DE) maltodextrin.
  • Suitable lipids include medium chain triglycerides (MCT) and long chain triglycerides (LCT).
  • MCT medium chain triglycerides
  • LCT long chain triglycerides
  • MCTs can comprise about 30 % to about 70 % by weight of the lipids, more specifically about 50 % to about 60 % by weight.
  • MCTs offer the advantage of easier digestion which can be important for humans with inflamed or compromised Gl tracts.
  • the lipids provide about 35 % to about 50 % of the energy of the nutritional composition.
  • the lipids can contain essential fatty acids (omega-3 and omega-6 fatty acids). Preferably these polyunsaturated fatty acids provide less than about 30 % of total energy of the lipid source.
  • Suitable sources of long chain triglycerides are rapeseed oil, sunflower seed oil, palm oil, soy oil, milk fat, corn oil, high oleic oils, and soy lecithin.
  • Fractionated coconut oils are a suitable source of medium chain triglycerides.
  • the lipid profile of the nutritional composition is preferably designed to have a polyunsaturated fatty acid omega-6 (n-6) to omega-3 (n-3) ratio of about 4:1 to about 10:1.
  • the n-6 to n-3 fatty acid ratio can be about 6:1 to about 9:1.
  • the nutritional composition may also include vitamins and minerals. If the nutritional composition is intended to be a sole source of nutrition, it preferably includes a complete vitamin and mineral profile.
  • vitamins include vitamins A, B-complex (such as Bl, B2, B6 and B12), C, D, E and K, niacin and acid vitamins such as pantothenic acid, folic acid and biotin.
  • minerals include calcium, iron, zinc, magnesium, iodine, copper, phosphorus, manganese, potassium, chromium, molybdenum, selenium, nickel, tin, silicon, vanadium and boron.
  • the nutritional composition can also include a carotenoid such as lutein, lycopene, zeaxanthin, and betacarotene.
  • a carotenoid such as lutein, lycopene, zeaxanthin, and betacarotene.
  • the total amount of carotenoid included can vary from about 0.001 pg/ml to about 10 pg/ml.
  • Lutein can be included in an amount of from about 0.001 pg/ml to about 10 pg/ml, preferably from about 0.044 pg/ml to about 5 pg/ml of lutein.
  • Lycopene can be included in an amount from about 0.001 pg/ml to about 10 pg/ml, preferably about 0.0185 pg/ml to about 5 pg/ml of lycopene.
  • Beta-carotene can comprise from about 0.001 pg/ml to about 10 mg/m
  • the nutritional composition preferably also contains reduced concentrations of sodium , for example, from about 300 mg/l to about 400 mg/l.
  • the remaining electrolytes can be present in concentrations set to meet needs without providing an undue renal solute burden on kidney function.
  • potassium is preferably present in a range of about 1180 to about 1300 mg/l
  • chloride is preferably present in a range of about 680 to about 800 mg/l.
  • the nutritional composition can also contain various other conventional ingredients such as preservatives, emulsifying agents, thickening agents, buffers, fibres and prebiotics (e.g. fructooligosaccharides, galactooligosaccharides), probiotics (e.g. B. animalis subsp. lactis BB-12, B. lactis HN019, B. lactis Bi07, B. infantis ATCC 15697, L. rhamnosus GG, L. rhamnosus HNOOI, L. acidophilus LA- 5, L. acidophilus NCFM, L. fermentum CECT5716, B. longum BB536, B. longum AH1205, B. longum AH1206, B.
  • prebiotics e.g. fructooligosaccharides, galactooligosaccharides
  • probiotics e.g. B. animalis subsp. lactis BB-12, B. lactis HN019, B. lactis
  • antioxidant/anti-inflammatory compounds including tocopherols, carotenoids, ascorbate/vitamin C, ascorbyl palmitate, polyphenols, glutathione, and superoxide dismutase (melon), other bioactive factors (e.g. growth hormones, cytokines, TFG-P), colorants, flavours, and stabilisers, lubricants, and so forth.
  • the nutritional composition is, in one embodiment, free from gluten.
  • the nutritional composition can be formulated as a soluble powder, a liquid concentrate, or a ready-to- use formulation.
  • the composition can be fed to a human in need via a nasogastric tube or orally.
  • Various flavours, fibres and other additives can also be present.
  • the nutritional compositions can be prepared by any commonly used manufacturing techniques for preparing nutritional compositions in solid or liquid form.
  • the composition can be prepared by combining various feed solutions.
  • a protein-in-fat feed solution can be prepared by heating and mixing the lipid source and then adding an emulsifier (e.g. lecithin), fat soluble vitamins, and at least a portion of the protein source while heating and stirring.
  • a carbohydrate feed solution is then prepared by adding minerals, trace and ultra-trace minerals, thickening or suspending agents to water while heating and stirring. The resulting solution is held for 10 minutes with continued heat and agitation before adding carbohydrates (e.g. the HMOs and digestible carbohydrate sources).
  • the resulting feed solutions are then blended together while heating and agitating and the pH adjusted to 6.6-7.0, after which the composition is subjected to high-temperature short-time processing during which the composition is heat treated, emulsified and homogenized, and then allowed to cool.
  • Water soluble vitamins and ascorbic acid are added, the pH is adjusted to the desired range if necessary, flavours are added, and water is added to achieve the desired total solid level.
  • the resulting solution can then be aseptically packed to form an aseptically packaged nutritional composition.
  • the nutritional composition can be in ready-to-feed or concentrated liquid form.
  • the composition can be spray-dried and processed and packaged as a reconstitutable powder.
  • the total concentration of the sialylated and/or the non-fucosylated neutral HMO in the liquid, by weight of the liquid is from about 0.1 % to about 1.5 %, including from about 0.2 % to about 1.0 %, for example from about 0.3 % to about 0.7 %.
  • the total concentration of the sialylated and/or the non-fucosylated neutral HMO in the liquid, by weight of the liquid is from about 0.2 % to about 3.0 %, including from about 0.4 % to about 2.0 %, for example from about 0.6 % to about 1.5 %.
  • the nutritional composition is in a unit dosage form.
  • the unit dosage form can contain an acceptable food-grade carrier, e.g. phosphate buffered saline solution, mixtures of ethanol in water, water and emulsions such as an oil/water or water/oil emulsion, as well as various wetting agents or excipients.
  • the unit dosage form can also contain other materials that do not produce an adverse, allergic or otherwise unwanted reaction when administered to a human.
  • the carriers and other materials can include solvents, dispersants, coatings, absorption promoting agents, controlled release agents, and one or more inert excipients, such as starches, granulating agents, microcrystalline cellulose, diluents, lubricants, binders, and disintegrating agents.
  • carriers and other materials are low in FODMAPs or contain no FODMAPs.
  • the unit dosage form comprises primarily the sialylated and/or the non-fucosylated neutral HMO with a minimum amount of binders and/or excipients. Unit dosage forms are particularly suitable when nutritionally incomplete or not intended as a sole source of nutrition.
  • a unit dosage form of this invention can be administered orally, e.g. as a tablet, capsule, or pellet containing a predetermined amount of the mixture, or as a powder or granules containing a predetermined concentration of the mixture or a gel, paste, solution, suspension, emulsion, syrup, bolus, electuary, or slurry, in an aqueous or non-aqueous liquid, containing a predetermined concentration of the mixture.
  • An orally administered composition can include one or more binders, lubricants, inert diluents, flavouring agents, and humectants.
  • An orally administered composition such as a tablet can optionally be coated and can be formulated to provide sustained or controlled release of the sialylated and/or the non-fucosylated neutral HMO.
  • a unit dosage form of this invention can also be administered by naso-gastric tube or direct infusion into the Gl tract or stomach.
  • a unit dosage form of this invention can also include therapeutic agents such as antibiotics, probiotics, analgesics, and anti-inflammatory agents.
  • the proper dosage of such a composition for a human can be determined in a conventional manner, based upon factors such as the human's condition, immune status, body weight and age. In some cases, the dosage will be at a concentration similar to that found for the 3'-SL and/or LNT of the composition in human breast milk.
  • the required amount would generally be in the range from about 0.1 g to about 10 g per day, in certain embodiments from about 0.2 g to about 7.5 g per day, for example about 1 g to about 5 g per day. Appropriate dose regimes can be determined by methods known to those skilled in the art.
  • the sialylated and/or the non-fucosylated neutral HMO can be formulated as a pharmaceutical composition.
  • the pharmaceutical composition can contain a pharmaceutically acceptable carrier, e.g. phosphate buffered saline solution, mixtures of ethanol in water, water and emulsions such as an oil/water or water/oil emulsion, as well as various wetting agents or excipients.
  • a pharmaceutically acceptable carrier e.g. phosphate buffered saline solution, mixtures of ethanol in water, water and emulsions such as an oil/water or water/oil emulsion, as well as various wetting agents or excipients.
  • the pharmaceutical composition can also contain other materials that do not produce an adverse, allergic or otherwise unwanted reaction when administered to humans.
  • the carriers and other materials can include solvents, dispersants, coatings, absorption promoting agents, controlled release agents, and one or more inert excipients, such as starches, granulating agents, microcrystalline cellulose, diluents, lubricants, binders, and disintegrating agents.
  • carriers and other materials are low in FODMAPs or contain no FODMAPs.
  • the pharmaceutical compositions can be administered orally, e.g. as a tablet, capsule, or pellet containing a predetermined amount, or as a powder or granules containing a predetermined concentration or a gel, paste, solution, suspension, emulsion, syrup, bolus, electuary, or slurry, in an aqueous or non-aqueous liquid, containing a predetermined concentration.
  • Orally administered compositions can include binders, lubricants, inert diluents, flavouring agents, and humectants.
  • Orally administered compositions such as tablets can optionally be coated and can be formulated to provide sustained, delayed or controlled release of the mixture therein.
  • the pharmaceutical compositions can also be administered by rectal suppository, aerosol tube, nasogastric tube or direct infusion into the Gl tract or stomach.
  • compositions can also include therapeutic agents such as antibiotics, probiotics, analgesics, and anti-inflammatory agents.
  • compositions for a human can be determined in a conventional manner, based upon factors such condition, immune status, body weight and age. In some cases, the dosage will be at a concentration similar to that found for the sialy lated and/or the non-fucosylated neutral HMO in human breast milk.
  • the required amount would generally be in the range from about 0.1 g to about 10 g per day, in certain embodiments from about 0.2 g to about 7.5 g per day, for example from about 1 g to about 5 g per day. Appropriate dose regimes can be determined by conventional methods.
  • the amount of the sia lylated and/or the non-fucosylated neutral HMO required to be administered will vary depending upon factors such as the risk and severity of the underlying condition, any other medical conditions or diseases, age, the form of the composition, and other medications being administered.
  • the amount may vary depending upon whether the combination is being used to deliver a direct effect [when the dose may be higher) or whether the combination is being used as a secondary prevention/maintenance (when the dose may be lower).
  • the required amount can be readily set by a medical practitioner and would generally be in the range from about 0.1 g to about 10 g per day, in certain embodiments from about 0.2 g to about 7.5 g per day, for example from about 1 g to about 5 g per day.
  • An appropriate dose can be determined based on several factors, including, for example, body weight and/or condition, the severity of the underlying condition being treated or prevented, other ailments and/or diseases, the incidence and/or severity of side effects and the manner of administration.
  • the dosing can be higher (for example 0.5 g to 10 g per day, preferably 1 g to 7.5 g per day).
  • the dosing can be reduced (for example, 0.1 g to 5 g per day, preferably 0.2 g to 3 g per day).
  • a ready to feed nutritional composition is prepared from water, maltodextrin, enzymatically hydrolysed whey protein (from cows milk), medium chain triglycerides (from coconut and/or palm kernel oil), corn-starch, soybean oil, soy lecithin, 3'-SL, LNT, magnesium chloride, calcium phosphate, guar gum, sodium ascorbate, potassium citrate, sodium phosphate, calcium citrate, choline chloride, potassium chloride, sodium citrate, magnesium oxide, taurine, L-carnitine, alpha-tocopheryl acetate, zinc sulphate, ferrous sulphate, niacinamide, calcium pantothenate, vitamin A palmitate, citric acid, manganese sulphate, pyridoxine hydrochloride, vitamin D3, copper sulphate, thiamine mononitrate, riboflavin, beta carotene, folic acid, biotin, potassium iodide, chromium chloride, sodium
  • the composition has a calorific density of 1.0 kcal/ml with a caloric distribution (% of kcal) as follows: protein: 16 %, carbohydrate: 51 %, fat: 33 %.
  • the protein source has an NPC:N ratio of 131:1.
  • the MCT:LCT ratio is 70:30 and the n6:n3 ratio is 7.4:1.
  • the osmolality is 270 when unflavoured.
  • the composition contains 85 % water and 1500 ml meets 100 % of the RDI for 22 key micronutrients.
  • the composition has a balanced peptide profile which promotes Gl absorption and integrity and the enzymatically hydrolysed 100 % whey protein facilitates gastric emptying.
  • the MCT decreases the potential for fat malabsorption.
  • the composition is nutritionally complete for tube feeding or oral supplementation.
  • a tablet is prepared from 3'-SL, LNT, hydroxypropyl methylcellulose, sodium alginate, gum, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate. All raw materials except the magnesium stearate are placed into a high shear granulator and premixed. Water is sprayed onto the premix while continuing to mix at 300 rpm. The granulate is transferred to a fluidised bed drier and dried at 75 °C. The dried powder is sieved and sized using a mill. The resulting powder is then lubricated with magnesium stearate and pressed into tablets.
  • the tablets each contain 325 mg of the combination of 3'-SL and LNT.
  • the tablets each have a weight of 750 mg.
  • a capsule is prepared by filling about 1 g of a combination of 3'-SL and LNT into a 000-gelatine capsule using a filing machine. The capsules are then closed. The 3'-SL and LNT are in free flowing, powder form.
  • Example 5 Nutritional composition
  • a combination of 3'-SL and LNT are introduced into a rotary blender in a 1:1 molar ratio.
  • An amount of 0.25 w% of silicon dioxide is introduced into the blender and the mixture blended for 10 minutes.
  • the mixture is then agglomerated in a fluidised bed and filled into 5 gram stick packs and the packs are sealed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des oligosaccharides de lait humain (HMO) destinés à être utilisés chez un nouveau-né pour lui prodiguer une meilleure qualité de sommeil et améliorer la durée de son sommeil nocturne.
PCT/IB2021/061288 2020-12-04 2021-12-03 Oligosaccharides de lait humain destinés à être utilisés pour favoriser la durée du sommeil nocturne Ceased WO2022118270A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063121367P 2020-12-04 2020-12-04
US63/121,367 2020-12-04

Publications (1)

Publication Number Publication Date
WO2022118270A1 true WO2022118270A1 (fr) 2022-06-09

Family

ID=81854008

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/061288 Ceased WO2022118270A1 (fr) 2020-12-04 2021-12-03 Oligosaccharides de lait humain destinés à être utilisés pour favoriser la durée du sommeil nocturne

Country Status (1)

Country Link
WO (1) WO2022118270A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024235730A3 (fr) * 2023-05-16 2024-12-26 Société des Produits Nestlé S.A. Composition nutritionnelle

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019087140A1 (fr) * 2017-11-02 2019-05-09 Glycom A/S Un ou plusieurs hmos pour réduire ou prévenir la fatigue et/ou améliorer la focalisation ou la concentration
WO2019111115A2 (fr) * 2017-12-05 2019-06-13 Glycom A/S Oligosaccharides du lait humain pour le traitement de la migraine
WO2019121929A1 (fr) * 2017-12-22 2019-06-27 Societe Des Produits Nestle S.A. Compositions destinées à être utilisées dans la réduction de la nociception chez des nourrissons et des enfants en bas âge
CN110651830A (zh) * 2019-09-29 2020-01-07 澳优乳业（中国）有限公司 一种改善睡眠的调制乳粉及其制备方法
CN112791151A (zh) * 2021-02-20 2021-05-14 山东新稀宝股份有限公司 一种具有改善睡眠功能的组合物及应用
WO2021105943A1 (fr) * 2019-11-27 2021-06-03 Glycom A/S Mélange de hmo

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019087140A1 (fr) * 2017-11-02 2019-05-09 Glycom A/S Un ou plusieurs hmos pour réduire ou prévenir la fatigue et/ou améliorer la focalisation ou la concentration
WO2019111115A2 (fr) * 2017-12-05 2019-06-13 Glycom A/S Oligosaccharides du lait humain pour le traitement de la migraine
WO2019121929A1 (fr) * 2017-12-22 2019-06-27 Societe Des Produits Nestle S.A. Compositions destinées à être utilisées dans la réduction de la nociception chez des nourrissons et des enfants en bas âge
CN110651830A (zh) * 2019-09-29 2020-01-07 澳优乳业（中国）有限公司 一种改善睡眠的调制乳粉及其制备方法
WO2021105943A1 (fr) * 2019-11-27 2021-06-03 Glycom A/S Mélange de hmo
CN112791151A (zh) * 2021-02-20 2021-05-14 山东新稀宝股份有限公司 一种具有改善睡眠功能的组合物及应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024235730A3 (fr) * 2023-05-16 2024-12-26 Société des Produits Nestlé S.A. Composition nutritionnelle

Similar Documents

Publication Publication Date Title
US9591872B2 (en) Nutritional composition for children with reflux, colic and/or constipation
US11278558B2 (en) Synthetic composition for microbiota modulation
JP2021504420A (ja) 微生物叢調節のためのヒトミルクオリゴ糖およびその合成組成物
RU2685187C2 (ru) Жидкая композиция обогатителя молока с относительно высоким содержанием липидов
US11541069B2 (en) One or more HMOs for reducing or preventing fatigue and/or improving focus or concentration
US11541067B2 (en) HMO compositions and methods for reducing detrimental proteolytic metabolites
WO2018207110A1 (fr) Composition synthétique pour la modulation du microbiote
CA3161861A1 (fr) Melange de hmo
US11602545B2 (en) Human milk oligosaccharides for treating migraine
US20230012011A1 (en) Mixture of hmos for improving the microbiota of pregnant women
EP3897663A1 (fr) Composition et méthode permettant de favoriser la cicatrisation de la barrière intestinale
BR112020022892A2 (pt) mistura de hmos para tratamento de doenças autoi-munes
CN104135872A (zh) 妊娠期间特定碳水化合物系统用于影响后代的用途
WO2022118270A1 (fr) Oligosaccharides de lait humain destinés à être utilisés pour favoriser la durée du sommeil nocturne
WO2022118269A1 (fr) Oligosaccharides de lait humain destinés à être utilisés pour permettre la maturation ou l'amélioration de rythmes de sommeil
CN105007756A (zh) 特定碳水化合物系统在怀孕期间用于防止孕妇的脂肪蓄积的用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21900201

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21900201

Country of ref document: EP

Kind code of ref document: A1